Northern Trust
TXMD icon

Northern Trust’s TherapeuticsMD TXMD Stock Holding History

Northern Trust’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.5K Sell
16,093
-355
-2% -$798 ﹤0.01% 4296
2025
Q4 		$26.8K Sell
16,448
-9
-0.1% -$13 ﹤0.01% 4363
2025
Q3 		$17.7K Hold
16,457
– – ﹤0.01% 4382
2025
Q2 		$19.1K Hold
16,457
– – ﹤0.01% 4337
2025
Q1 		$15.2K Hold
16,457
– – ﹤0.01% 4365
2024
Q4 		$14.2K Hold
16,457
– – ﹤0.01% 4402
2024
Q3 		$27.3K Hold
16,457
– – ﹤0.01% 4303
2024
Q2 		$26.5K Hold
16,457
– – ﹤0.01% 4302
2024
Q1 		$37.7K Sell
16,457
-34
-0.2% -$79 ﹤0.01% 4264
2023
Q4 		$37.1K Hold
16,491
– – ﹤0.01% 4281
2023
Q3 		$49.8K Hold
16,491
– – ﹤0.01% 4169
2023
Q2 		$67.9K Buy
16,491
+766
+5% +$3K ﹤0.01% 4137
2023
Q1 		$59K Hold
15,725
– – ﹤0.01% 4221
2022
Q4 		$87.9K Buy
+15,725
New +$92.6K ﹤0.01% 4128
2022
Q3 		– Sell
-13,956
Closed -$139K – 4761
2022
Q2 		$139K Sell
13,956
-56,778
-80% -$542K ﹤0.01% 4056
2022
Q1 		$1.34M Sell
70,734
-2,875
-4% -$45.2K ﹤0.01% 3284
2021
Q4 		$1.31M Sell
73,609
-8,431
-10% -$253K ﹤0.01% 3435
2021
Q3 		$3.04M Buy
82,040
+4,121
+5% +$183K ﹤0.01% 3049
2021
Q2 		$4.64M Buy
77,919
+3,597
+5% +$218K ﹤0.01% 2882
2021
Q1 		$4.98M Buy
74,322
+16,341
+28% +$1.28M ﹤0.01% 2745
2020
Q4 		$3.51M Buy
57,981
+1,657
+3% +$113K ﹤0.01% 2881
2020
Q3 		$4.45M Sell
56,324
-2,773
-5% -$221K ﹤0.01% 2617
2020
Q2 		$3.69M Buy
59,097
+5,502
+10% +$320K ﹤0.01% 2698
2020
Q1 		$2.84M Sell
53,595
-181
-0.3% -$17.9K ﹤0.01% 2649
2019
Q4 		$6.51M Sell
53,776
-11,776
-18% -$1.69M ﹤0.01% 2434
2019
Q3 		$11.9M Buy
65,552
+18,427
+39% +$2.6M ﹤0.01% 2031
2019
Q2 		$6.13M Buy
47,125
+403
+0.9% +$72.2K ﹤0.01% 2449
2019
Q1 		$11.4M Buy
46,722
+909
+2% +$241K ﹤0.01% 2065
2018
Q4 		$8.73M Sell
45,813
-262
-0.6% -$63.9K ﹤0.01% 2176
2018
Q3 		$15.1M Buy
46,075
+4,344
+10% +$1.33M ﹤0.01% 1997
2018
Q2 		$13M Buy
41,731
+1,621
+4% +$495K ﹤0.01% 2086
2018
Q1 		$9.77M Sell
40,110
-125
-0.3% -$35.1K ﹤0.01% 2182
2017
Q4 		$12.2M Buy
40,235
+1,317
+3% +$367K ﹤0.01% 2062
2017
Q3 		$10.3M Sell
38,918
-2,286
-6% -$661K ﹤0.01% 2190
2017
Q2 		$10.9M Buy
41,204
+3,842
+10% +$962K ﹤0.01% 2119
2017
Q1 		$13.4M Buy
37,362
+2,037
+6% +$630K ﹤0.01% 1897
2016
Q4 		$10.2M Buy
35,325
+409
+1% +$127K ﹤0.01% 2101
2016
Q3 		$11.9M Buy
34,916
+194
+0.6% +$70.9K ﹤0.01% 1949
2016
Q2 		$14.8M Buy
34,722
+1,821
+6% +$750K ﹤0.01% 1752
2016
Q1 		$10.5M Buy
32,901
+3,514
+12% +$1.2M ﹤0.01% 1943
2015
Q4 		$15.2M Buy
29,387
+1,155
+4% +$426K 0.01% 1703
2015
Q3 		$8.27M Buy
28,232
+2,112
+8% +$751K ﹤0.01% 2125
2015
Q2 		$10.3M Buy
26,120
+2,277
+10% +$803K ﹤0.01% 2055
2015
Q1 		$7.21M Buy
23,843
+859
+4% +$210K ﹤0.01% 2276
2014
Q4 		$5.11M Sell
22,984
-805
-3% -$166K ﹤0.01% 2491
2014
Q3 		$5.52M Buy
23,789
+4,150
+21% +$1.05M ﹤0.01% 2442
2014
Q2 		$4.34M Sell
19,639
-1,995
-9% -$444K ﹤0.01% 2609
2014
Q1 		$6.83M Sell
21,634
-378
-2% -$120K ﹤0.01% 2367
2013
Q4 		$5.73M Buy
22,012
+3,994
+22% +$875K ﹤0.01% 2462
2013
Q3 		$2.64M Buy
18,018
+12,699
+239% +$1.54M ﹤0.01% 2927
2013
Q2 		$805K Buy
+5,319
New +$729K ﹤0.01% 3329

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust's TXMD Position: Q1 2026 in Review

Northern Trust reduced its TherapeuticsMD (TXMD) stake by 2.2% in Q1 2026, selling an estimated $798 and leaving 16,093 shares worth $32.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4296.

Northern Trust first reported a position in TXMD in Q2 2013 and has held it in 51 quarters since. The position peaked at $15.2M in Q4 2015. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Northern Trust held 16,093 shares of TherapeuticsMD worth $32.5K as of Q1 2026.
  • Northern Trust sold 355 TherapeuticsMD shares in Q1 2026, an estimated $798.
  • TherapeuticsMD made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4296 holding.
  • Northern Trust first reported a position in TherapeuticsMD in Q2 2013 and has held it in 51 quarters since.
  • Northern Trust's TherapeuticsMD position peaked at $15.2M in Q4 2015.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.